A recent issue of medical journal BMJ included the report of a study conducted by a team of French and Brazilian scientists. After reviewing the diets and medical records of 104,980 French adults, the researchers found that an increase in consumption of processed foods paralleled an increase in cancer risk.
Specifically, data showed that eating 10 percent more highly processed foods was accompanied by a 12 percent increase in overall cancer risk and 11 percent increase in breast cancer risk.
Items defined as “highly processed foods” included ready-to-eat meals, carbonated drinks and reconstituted meat found in products like chicken nuggets. According to the research team, these types of foods constitute nearly half of the energy intake in many developed countries.
Making Healthy Choices
No link was found with moderately processed foods such as cheese, canned vegetables and freshly made bread. Not surprisingly, minimally processed foods such as fruits and vegetables, meat, eggs and fish were linked to a lower risk of cancer.
The team said that study limitations prevented firm conclusions. Further research can clarify the implications and help to identify the specific elements in foods that link to cancer.
Issels®: The Leader in Immunotherapy Cancer Treatment
At Issels®, nutritional immunotherapy is one of the components in our individually developed cancer treatment programs. Contact us for more information about our non-toxic, state-of-the-art immunotherapy treatments.
Cancer Research UK and Biotecnol Limited are collaborating on development of a first-in-class Fdrug known as Tb535H. Arising from Trisoma®, Biotecnol’s antibody development platform, the drug targets the 5T4/WAIF1 antigen that is believed to contribute to the spread of cancer cells.
As with most immunotherapy treatments, Tb535H works by harnessing the immune system’s T cells and directing them to attack and kill cancer cells. Biotecnol has been instrumental in partnering with top cancer institutions to develop promising immune-oncology therapies.
Targeted Cancer Treatment
The discovery of the WAIF1 antigen also occurred as a result of studies at Cancer Research UK’s Manchester Institute. While it may ultimately be a target for a number of cancer types, current testing will be limited to cancers with low survival rates, including mesothelioma and small-cell lung carcinoma.
Dr. Nigel Blackburn, director of drug development for Cancer Research UK, acknowledged that the partnership with Biotecnol will accelerate the path of bringing Tb535H to cancer patients. Blackburn also stressed the need for more effective treatment for lung cancer, the cause of 20 percent of cancer deaths in the UK.
While immunotherapy is a hot buzzword in cancer treatment today, we have been using non-toxic integrative programs for decades. Contact us to read and hear testimonials from patients with all forms of cancer who have received successful treatment at Issels®.